Movement Alert|Salesforce.com Intraday Rise 13.1%, Q2 Earnings Significantly Beat Expectations With Anthropic Partnership Accelerating AI Commercialization

Market Focus
Yesterday

On August 27, Salesforce.com rose 13.1% in regular trading, trading at $238.01/share, with turnover of $1.336 billion. The surge was driven by a strong fiscal Q2 earnings report and an expanded strategic partnership with Anthropic.

Salesforce.com reported Q2 FY2027 revenue of $11.35 billion, up 11% year-over-year, with adjusted EPS of $5.90 — beating the consensus estimate of $3.27 by over 80%. GAAP net income reached $3.53 billion, up 87% year-over-year. The company raised full-year revenue guidance to $46.1B-$46.4B and EPS guidance to $16.67-$16.71, far exceeding the prior consensus of $14.17. Q3 revenue guidance of $11.42B-$11.5B also topped expectations.

Simultaneously, the company announced an expanded partnership with Anthropic to launch Claudeforce, with AI and data product ARR approaching $4 billion. Multiple institutions raised price targets, with Truist Securities lifting to $300 and TD Cowen to $280. The company also noted no significant additional restructuring costs are expected near-term, further clarifying the financial outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10